Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

Global Nanopore Sequencing Market OverviewThe nanopore sequencing market is projected to grow at a CAGR of around 11% during the forecast period, driven by rising demand for real-time, portable DNA ...

Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...

Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...

Accelerated sequencing technologies, AI-enabled analytics, newborn screening expansion, and government-backed genomic initiatives fuel rapid growth across North America, Europe, and ...

The global digestive health market is booming, valued at $51bn (€43bn) and projected to reach $68bn by 2030 with an 8.3% CAGR ...

We call him the Evil Genius for a reason. Green helped define the early 2000s — an architect of the mixtape golden age who ...

The bank’s ‘Today, Tomorrow, Forever’ framework helps families organise and navigate their wealth across three interconnected ...

On November 26, 2025, the United States Patent and Trademark Office (USPTO) issued revised guidelines for determining inventorship of ...